RESEARCH: Clinical Trials

back to Clinical Trials

KNOPP

• The primary objective of the study is to evaluate the safety and tolerability of oral administration of 3 dosage levels of KNS760704 (a drug very similar to a drug that has been FDA approved for treatment of symptoms in Parkinson's disease) compared to placebo for 12 weeks in patients with ALS.
  
  
• The secondary objectives are below:
  
  • To evaluate the safety and tolerability of oral administration of 2 dosage levels of KNS-760704 for 6 months in ALS patients (Part 2)
  • To evaluate the effects of KNS-760704 on measures of clinical function
  • To evaluate the reliability and clinical predictive value of upright and supine forced vital capacity (FVC)
  • To evaluate the effects of KNS-760704 on selected protein levels in blood and cerebrospinal fluid (CSF)

For further information, please contact Kate Dalton: keb2114@columbia.edu and phone number (212) 305-2027.